 Clene Nanomedicine

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY, July 19, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported that it has received a positive opinion for its submission requesting Orphan Drug Designation for CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).

Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS

The company's lead therapy has shown progress against ALS in preliminary trials.

Why Shares of Clene Jumped 11.8% on Monday

H.C. Wainwright initiated coverage on Clene Inc (NASDAQ: CLNN) with a Buy rating and a $16 price target.  Clene is focused on the development of novel clean-surfaced nanotechnologies consisting of transition element nanocrystals for central nervous disorders, such as.

HC Wainwright Initiates Coverage On This Nanocrystals Stock

Cemtrex

OceanPal

Penny stocks to watch right now. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 3 For Your July Watch List

Canoo

SaverOne 2014 Ltd

Which penny stocks are you watching right now? The post Hot Penny Stocks to Watch Today?

Hot Penny Stocks to Watch Today? 3 For Your List in July

Clene (CLNN) stock is heading higher on Thursday following the release of data from a long-term clinical trial of CNM-Au8. The post Why Is Clene (CLNN) Stock Soaring 23% Today?

Why Is Clene (CLNN) Stock Soaring 23% Today?

Clene Inc (NASDAQ: CLNN) reported significantly improved survival in Amyotrophic lateral sclerosis (ALS) patients initially treated with CNM-Au8 compared to initially randomized placebo-treated participants during the long-term open-label extension of its RESCUE-ALS trial. Rob.

Clene's CNM-Au8 Shows Decreased Mortality Amyotrophic Lateral Sclerosis Patients

SALT LAKE CITY, July 14, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported significantly improved survival in ALS patients initially treated with CNM-Au8 compared to initially randomized placebo treated participants during the long-term open-label extension of its RESCUE-ALS trial.

Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial

SALT LAKE CITY, June 27, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that Rob Etherington, the Company's President and CEO, has been invited to participate in the “Innovations in ALS - Exploring New Treatments In Development” virtual panel presented by Maxim Group LLC and hosted by M-Vest at 11 a.m. EDT on Tuesday, June 28. M-Vest members can follow the live event live here. At the same link, non-members can sign up.

Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28

Clene Inc. (NASDAQ: CLNN) shares are trading higher by 10.81% at $2.46 after the company received a $3 million loan from the Maryland Board of Public Works to support production for its lead drug candidate CNM-Au8. Clene says this non-dilutive loan for capital equipment purchases will support the.

Why Clene Shares Are Rising

$3 million 60-month loan to support capital equipment purchases in new 75,000-square-foot facility in Elkton, Maryland, for manufacture of Clene's lead drug candidate, CNM-Au8®, for treatment of ALS

Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility

SALT LAKE CITY, May 09, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its first quarter 2022 and recent operating highlights.

Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights

Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode Results show significant survival benefit in participants who entered open-label extension of study of CNM-Au8®, a gold nanocrystal suspension, compared to validated ENCALS prediction mode

Updated Interim Data from Clene Nanomedicine's RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting

SALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today reported its full year 2021 operating and financial results, as well as an overview of fourth quarter 2021 and recent operating highlights.

Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights

SALT LAKE CITY, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced the presentation of updated blinded interim data from its VISIONARY-MS study and results from its REPAIR-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place Feb. 24-26, 2022, in West Palm Beach, Fla. These data further support Clene's lead drug candidate, CNM-Au8®, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for Multiple Sclerosis (MS).

Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022

SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced that it will present updated blinded data from its VISIONARY-MS study and results from its REPAIR-MS trial in the stable relapsing MS population at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, taking place from Feb. 24-26, 2022, in West Palm Beach, Fl.

Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022

SALT LAKE CITY, Feb. 14, 2022 (GLOBE NEWSWIRE) --  Clene Inc. (NASDAQ: CLNN) along with its wholly owned subsidiary Clene Nanomedicine, Inc. (Clene) is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease. Today, Clene provided clinical program updates for its lead nanotherapeutic platform drug candidate: CNM-Au8®, as well as its antiviral candidate, CNM-ZnAg. CNM-Au8 is a gold nanocrystal suspension, developed to increase cellular energy production and utilization to restore neuronal health. CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antimicrobial properties.

Clene Nanomedicine Provides Clinical Program Update

SALT LAKE CITY, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced it has enrolled more than 50% of the approximately 276 planned participants for its Phase 2 multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients in Brazil. CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity.

Clene Nanomedicine's Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial

Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022

Clene Nanomedicine's Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe

The stock price of Clene Inc. (NASDAQ: CLNN) increased by 13.12% in the most recent trading session. This is why it happened.

Clene Stock (CLNN): Why The Price Increased

SALT LAKE CITY, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS) in a late-breaking oral presentation at the 32nd International Symposium on ALS/MND, Dec. 10, 2021 at 1:05 pm ET. The presentation can be viewed after the presentation on Clene's website at: https://invest.clene.com/overview/default.aspx.

Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND

SALT LAKE CITY, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, announced the 32nd International Symposium on ALS/MND, a Motor Neurone Disease (MND) Association event, has selected Clene's Phase 2 RESCUE-ALS clinical trial results of CNM-Au8®, a gold nanocrystal suspension, in the treatment of amyotrophic lateral sclerosis (ALS) for a late-breaking oral presentation as well as a poster presentation.

Clene Nanomedicine's RESCUE-ALS Phase 2 Results Selected for Late-Breaking Presentation at 32nd International Symposium on ALS/MND

Clene Inc. (CLNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Clene Inc. (CLNN) Upgraded to Buy: What Does It Mean for the Stock?

The consensus price target hints at a 287.8% upside potential for Clene Inc. (CLNN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Clene Inc. (CLNN) Could Rally 288%: Here's is How to Trade

Clene Inc (NASDAQ: CLNN) presented new data from the RESCUE-ALS Phase 2 study of CNM-Au8, a catalytically active gold nanocrystal suspension for amyotrophic lateral sclerosis (ALS). Data were shared at the 4th Annual ALS ONE Research Symposium.

News for Clene Nanomedicine Stock (CLNN)